FDA’s approval of Amgen’s osteoporosis treatment, Prolia (denosumab), came with strings attached. Postmarket surveillance requirements – including Phase IV trials and studies – are increasingly part of the FDA approval pathway in the 21st century. There are a number of reasons for this, including … Continue reading at ComplianceZen.com →
Menu